Viking Therapeutics Inc Stock
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | -5.100% | 10.031% | -1.698% | 270.425% | 304.003% | 1227.820% | - |
| Ardelyx Inc. | 30.240% | 7.123% | -7.526% | 58.693% | 9.273% | 3.541% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | -5.069% | 5.641% | -71.389% | -25.766% | -98.474% | -99.994% |
| Brainstorm Cell | 5.560% | -26.131% | -44.654% | -86.685% | 58.405% | -87.328% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.
1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.
2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.
News
Is Viking Therapeutics Incredibly Undervalued?
Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled
Can This High-Flying Stock 10x in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V (NYSE: NVO) with its Semaglutide medications
